IL-23/CGRP bispecific antibody (Eli Lilly)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameIL-23/CGRP bispecific antibody (Eli Lilly)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCalcitonin gene-related peptide receptor antagonistsInterleukin-23 inhibitors

TargetsCalcitonin gene-related peptide receptorInterleukin-23

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesEli Lilly And Company

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEli Lilly And Company

Active IndicationsN/A

Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A